Detalhe da pesquisa
1.
Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.
J Immunol
; 187(2): 1039-46, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21653833
2.
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.
J Immunol
; 187(4): 1998-2005, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21775681
3.
Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34266886
4.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Clin Immunol
; 132(2): 166-73, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19443276
5.
Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.
J Neuroimmunol
; 177(1-2): 151-60, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16806500
6.
Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Ralpha) in peripheral blood from patients with multiple sclerosis (MS).
J Neuroimmunol
; 222(1-2): 82-6, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20226540
7.
Identification of a B cell signature associated with renal transplant tolerance in humans.
J Clin Invest
; 120(6): 1836-47, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501946